StockData
ADC Therapeutics SA logo

ADC Therapeutics SA (ADCT) stock

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.37+0.02 (+1.48%)

Close on Nov 18, 2026Market cap $174.91MP/E –Yield –

ADC Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

ADC Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$100.55M. For fiscal 2025 it was -$141.44M. The highest annual figure on record is -$121.90M in fiscal 2023.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$141.44M–
FY2024Dec 31, 2024-$124.70M–
FY2023Dec 31, 2023-$121.90M–
FY2022Dec 31, 2022-$139.00M–
FY2021Dec 31, 2021-$236.81M–
FY2020Dec 31, 2020-$169.53M–
FY2019Dec 31, 2019-$121.94M–
FY2018Dec 31, 2018-$122.31M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$27.88M–
Q2 FY2026Jun 30, 2026-$11.81M–
Q1 FY2026Mar 31, 2026-$29.74M–
Q4 FY2025Dec 31, 2025-$31.12M–
Q3 FY2025Sep 30, 2025-$29.63M–
Q2 FY2025Jun 30, 2025-$24.09M–
Q1 FY2025Mar 31, 2025-$56.60M–
Q4 FY2024Dec 31, 2024-$21.94M–
Q3 FY2024Sep 30, 2024-$25.26M–
Q2 FY2024Jun 30, 2024-$32.88M–
Q1 FY2024Mar 31, 2024-$44.63M–
Q4 FY2023Dec 31, 2023-$31.96M–
Q3 FY2023Sep 30, 2023-$37.33M-1965.8%
Q2 FY2023Jun 30, 2023-$36.20M–
Q1 FY2023Mar 31, 2023-$16.41M–
Q4 FY2022Dec 31, 2022-$53.83M–
Q3 FY2022Sep 30, 2022$2.00M–
Q2 FY2022Jun 30, 2022-$53.06M–
Q1 FY2022Mar 31, 2022-$34.11M–
Q4 FY2021Dec 31, 2021-$62.05M–
Q3 FY2021Sep 30, 2021-$59.99M–
Q2 FY2021Jun 30, 2021-$58.96M–
Q1 FY2021Mar 31, 2021-$55.81M–
Q4 FY2020Dec 31, 2020-$51.87M–
Q3 FY2020Sep 30, 2020-$44.69M–
Q2 FY2020Jun 30, 2020-$40.77M–
Q1 FY2020Mar 31, 2020-$32.20M–

More ADC Therapeutics figures

See a number that looks wrong?